Chelsea Therapeutics International Ltd. (CHTP) - Financial and Strategic SWOT Analysis Review

Date: April 15, 2014
Pages: 35
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C272C5AA828EN
Leaflet:

Download PDF Leaflet

Chelsea Therapeutics International Ltd. (CHTP) - Financial and Strategic SWOT Analysis Review
Chelsea Therapeutics International Ltd. (CHTP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Chelsea Therapeutics International Ltd. (Chelsea Therapeutics) is an early stage pharmaceutical company that focuses on acquiring and developing products for the treatment of an array of human diseases. It mainly focuses on the development of drugs and technologies for the treatment of rheumatoid arthritis, autonomic nervous system conditions, psoriasis, inflammatory bowel disease, cancer and other disorders.

Chelsea Therapeutics International Ltd. Key Recent Developments

Jan 30, 2014: Chelsea Therapeutics Names Keith W. Schmidt Chief Commercial Officer
Jan 27, 2014: Chelsea Therapeutics Announces Joseph G. Oliveto Named President and Chief Executive Officer, Director
Nov 18, 2013: Chelsea Therapeutics completes public offering of common stock
Nov 13, 2013: Chelsea Therapeutics announces public offering of common stock
Nov 05, 2013: Chelsea Therapeutics Reports Third Quarter 2013 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Chelsea Therapeutics International Ltd. - Key Facts
Chelsea Therapeutics International Ltd. - Key Employees
Chelsea Therapeutics International Ltd. - Key Employee Biographies
Chelsea Therapeutics International Ltd. - Major Products and Services
Chelsea Therapeutics International Ltd. - History
Chelsea Therapeutics International Ltd. - Company Statement
Chelsea Therapeutics International Ltd. - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Chelsea Therapeutics International Ltd. - Business Description
Chelsea Therapeutics International Ltd. - Corporate Strategy
Chelsea Therapeutics International Ltd. - SWOT Analysis
SWOT Analysis - Overview
Chelsea Therapeutics International Ltd. - Strengths
Strength - Sturdy R&D Activities
Strength - Northera (droxidopa)-Orphan Drug status
Chelsea Therapeutics International Ltd. - Weaknesses
Weakness - Lack of Product Based Revenues
Weakness - Dependence on Third-Parties
Chelsea Therapeutics International Ltd. - Opportunities
Opportunity - Strong Pipeline Portfolio
Opportunity - Changing Demographics
Opportunity - Market Potential: CNS Therapy
Chelsea Therapeutics International Ltd. - Threats
Threat - Intense Competition
Threat - Uncertain R&D Outcomes
Threat - Stringent Government Regulations
Chelsea Therapeutics International Ltd. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Chelsea Therapeutics International Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Chelsea Therapeutics International Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Chelsea Therapeutics International Ltd., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Chelsea Therapeutics International Ltd., Recent Developments
Jan 30, 2014: Chelsea Therapeutics Names Keith W. Schmidt Chief Commercial Officer
Jan 27, 2014: Chelsea Therapeutics Announces Joseph G. Oliveto Named President and Chief Executive Officer, Director
Nov 18, 2013: Chelsea Therapeutics completes public offering of common stock
Nov 13, 2013: Chelsea Therapeutics announces public offering of common stock
Nov 05, 2013: Chelsea Therapeutics Reports Third Quarter 2013 Financial Results
Sep 19, 2013: Chelsea Therapeutics to Present at BioCentury's 2013 Newsmakers in the Biotech Industry Conference
Aug 07, 2013: Chelsea Therapeutics to Present at the 2013 Wedbush Life Sciences Management Access Conference
Aug 06, 2013: Chelsea Therapeutics Reports Second Quarter 2013 Financial Results
Jul 01, 2013: Chelsea Therapeutics Added to Russell 3000 and Russell 2000 Indexes
May 01, 2013: Chelsea Therapeutics Reports Q1 2013 Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Chelsea Therapeutics International Ltd., Key Facts
Chelsea Therapeutics International Ltd., Key Employees
Chelsea Therapeutics International Ltd., Key Employee Biographies
Chelsea Therapeutics International Ltd., Major Products and Services
Chelsea Therapeutics International Ltd., History
Chelsea Therapeutics International Ltd., Key Competitors
Chelsea Therapeutics International Ltd., Ratios based on current share price
Chelsea Therapeutics International Ltd., Annual Ratios
Chelsea Therapeutics International Ltd., Interim Ratios
Chelsea Therapeutics International Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Chelsea Therapeutics International Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Chelsea Therapeutics International Ltd., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Chelsea Therapeutics International Ltd., Performance Chart (2009 - 2013)
Chelsea Therapeutics International Ltd., Ratio Charts
Chelsea Therapeutics International Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Chelsea Therapeutics International Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Skip to top


Ask Your Question

Chelsea Therapeutics International Ltd. (CHTP) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: